Emergent Biosolutions Inc. (NYSE:EBS) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts rate Emergent BioSolutions “Hold” on average: Two analysts recommend selling, one recommends holding, and three recommend buying. The average 12-month price target is $10, compared with the stock’s opening price of $5.67.
• The stock has declined significantly: Shares were down 5.6%, with the 50-day and 200-day moving averages at $6.54 and $7.80, respectively. Emergent’s market capitalization is approximately $290 million.
• Quarterly results exceeded expectations: The company reported adjusted EPS of $0.60 versus the consensus estimate of a $0.08 loss, while revenue reached $234.3 million, above the $177.5 million forecast.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have commented on EBS shares. Benchmark restated a "buy" rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Emergent Biosolutions in a research note on Wednesday. Zacks Research raised Emergent Biosolutions to a "hold" rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. started coverage on Emergent Biosolutions in a research note on Friday, August 21st. They set an "underweight" rating on the stock. Finally, Weiss Ratings upgraded Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st.

Emergent Biosolutions Stock Down 5.6%

Shares of Emergent Biosolutions stock opened at $5.67 on Thursday. The stock's 50-day moving average is $6.54 and its 200 day moving average is $7.80. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06. The firm has a market cap of $290.44 million, a price-to-earnings ratio of -1.60 and a beta of 2.34. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. Equities research analysts anticipate that Emergent Biosolutions will post 0.13 EPS for the current year.

Insider Activity

In other Emergent Biosolutions news, SVP Paul Williams sold 3,000 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC bought a new position in Emergent Biosolutions in the 2nd quarter valued at about $29,000. CANADA LIFE ASSURANCE Co bought a new stake in Emergent Biosolutions during the 4th quarter worth approximately $45,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Emergent Biosolutions in the second quarter worth approximately $36,000. Legal & General Group Plc bought a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $31,000. Finally, California State Teachers Retirement System boosted its position in shares of Emergent Biosolutions by 112.8% during the second quarter. California State Teachers Retirement System now owns 6,008 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 3,185 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.